Arlington VA 黑色素瘤临床试验
20项针对 黑色素瘤的研究正在 Arlington及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
招募中2 期
- Inova Schar Cancer Institute ( Site 4046), Fairfax · 距离 11 英里
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
招募中1 期
- Inova Schar Cancer Infusion Pharmacy, Fairfax · 距离 11 英里
- Inova Schar Cancer, Fairfax · 距离 11 英里
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
招募中2 期
- Inova Fairfax Hospital, Falls Church · 距离 4 英里
- Inova Schar Cancer Institute, Fairfax · 距离 11 英里
- Inova Fair Oaks Hospital, Fairfax · 距离 11 英里
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
招募中3 期
- Inova Schar Cancer Institute, Fairfax · 距离 11 英里
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
招募中1/2 期
- Virginia Cancer Specialists-Fairfax, Fairfax · 距离 11 英里
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
招募中1 期
- Virginia Cancer Specialists, Fairfax · 距离 11 英里
Project: Every Child for Younger Patients With Cancer
招募中观察性研究
- Inova Fairfax Hospital, Falls Church · 距离 4 英里
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
招募中1/2 期
- Research Site, Fairfax · 距离 11 英里
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
招募中1/2 期
- Clinical Trial Site, Fairfax · 距离 11 英里
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
招募中1/2 期
- Virginia Cancer Specialists, Fairfax · 距离 11 英里
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
招募中1 期
- NEXT Virginia, Fairfax · 距离 11 英里
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
招募中1/2 期
- Next Oncology Virginia, Fairfax · 距离 11 英里
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
招募中1 期
- NEXT Oncology - Virginia, Fairfax · 距离 11 英里
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
招募中1 期
- NEXT Virginia, Fairfax · 距离 11 英里
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
招募中1 期
- NEXT Oncology, Fairfax · 距离 11 英里
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
招募中1/2 期
- Research Site 102, Fairfax · 距离 11 英里
- Research Site 112, Fairfax · 距离 11 英里
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
招募中1/2 期
- Virginia Cancer Specialists, Fairfax · 距离 11 英里
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
招募中1/2 期
- Virginia Cancer Specialists, Fairfax · 距离 11 英里
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
招募中1/2 期
- NEXT Virginia, Fairfax · 距离 11 英里
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
招募中1 期
- Next Oncology, Virginia Cancer Specialists, Fairfax · 距离 11 英里
其他城市的 黑色素瘤试验
- Houston, TX59 项研究
- New York City, NY38 项研究
- Los Angeles, CA34 项研究
- Nashville, TN32 项研究
- Pittsburgh, PA31 项研究
- Boston, MA25 项研究
- Philadelphia, PA23 项研究
- San Francisco, CA22 项研究
- Atlanta, GA21 项研究
- Columbus, OH21 项研究
- Salt Lake City, UT21 项研究
- Durham, NC21 项研究
Arlington的其他研究
- 非小细胞肺癌104 项研究
- 转移性癌症53 项研究
- 结直肠癌52 项研究
- 癌症（所有类型）48 项研究
- 卵巢癌46 项研究
- 乳腺癌46 项研究
- 肺癌40 项研究
- 子宫内膜癌39 项研究
- 胰腺癌34 项研究
- 头颈鳞状细胞癌26 项研究
- 小细胞肺癌23 项研究
- 三阴性乳腺癌20 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月1日。每项研究自行设定入选标准，由研究团队决定谁能参与。